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Objective: The aim of this study was to compare the therapeutic effect of sacroiliac (SI) blockade in 
patients with and without lumbosacral fusion.
Methods: This study included 72 patients diagnosed with SI pain and who received blockade injec-
tion (methylprednisolone and lidocaine). Patients were divided into 2 groups; 22 patients in the fusion 
group who underwent previous lumbosacral fusion and 50 patients in the non-fusion group. Average 
follow-up was 17.7 (range: 6 to 30) months. All patients were evaluated before and after intervention 
using the Visual Analog Scale (VAS), Oswestry Disability Index, Rivermead Mobility Index and SF-
36. Results were statistically analyzed.
Results: Activity pain (a component of VAS) was significantly better in the non-fusion group than the 
fusion group (p=0.042). No other statistically significant differences were observed between groups 
(p>0.05).
Conclusion: Sacroiliac blockade has a similar therapeutic effect on patients who underwent lumbosa-
cral fusion surgery as on non-operated patients in the middle-term. Therefore, alternative treatment 
options are not necessary in patients with fusion.
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Spinal instrumentation and fusion is a surgical interven-
tion that changes the biomechanics of the spine and load 
distribution. Therefore, ‘adjacent segment degeneration’ 
has gradually become more popular. Adjacent segment 
degeneration caused by excessive stress formed at the in-
ferior and superior part of the rigid segment impairs the 
success of the original operation and frequently requires 
treatment. Distal adjacent level is accepted as the sacro-
iliac (SI) joint in the presence of a fusion terminated in 
the lower lumbar part.[1] Sacroiliac joint degeneration is 
considered responsible for new onset of posterior pain 
developing after spinal fusion operation.[2] Sacroiliac 
problems are more often seen when the sacrum is in-
volved in the fusion.[1,3,4]
The effectiveness of injection treatments is contro-
versial in SI pain. A review of literature data reveals little 
evidence of the effectiveness of corticosteroid injections.
[5] However, injections continue to be used due to the ab-
sence of a clear consensus about different SI joint treat-
ments and their less invasive nature.[6]
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The aim of this study was to compare the results of 
corticosteroid injection for the treatment of SI pain be-
tween patients who underwent lumbosacral fusion sur-
gery and those who did not.
Patients and methods
Approval for this prospective study was obtained from 
the ethics committee of our institution. The study in-
cluded 112 patients diagnosed with SI pain and who 
responded positively to SI injection between 2009 and 
2012. Diagnosis of SI pain was determined by either 
arthrotic findings on X-rays or through positive sacral 
and pelvic compression tests. Of the 112 patients, 22 
had previously undergone lumbar spinal fusion surgery. 
Positive response to SI injection was considered a 75% 
or greater reduction in pain prompted by compression 
testing 1 to 8 hours following injection.[7] Patients with 
syndromes, neuromuscular diseases, history of spondy-
loarthropathy, decompensated metabolic diseases, histo-
ry of coagulopathy, allergy to medications and pregnant 
patients were excluded from the study. Patients whose 
fusion was terminated above the sacrum were not in-
cluded in the fusion group. Twenty-eight patients were 
excluded from the study as they did not complete the 
follow-up and 12 patients were excluded as they tried 
different therapies after the injection.
The remaining 72 patients were enrolled in the study 
as two groups. The fusion group comprised the 22 pa-
tients who underwent previous spinal fusion surgery 
and the non-fusion group the 50 non-operated patients 
(Fig. 1).
Patients were informed about the process and po-
tential complications and their written consent was 
obtained. With the patient in the prone position, the 
estimated access point was marked on the skin through 
observation of the inferior part of the SI joint. Injection 
was performed from the standard entrance portal under 
fluoroscopy guidance. A 22-gauge spinal needle was ad-
vanced to the joint space parallel to the angle of the C-
arm from the access point marked on the skin. 0.5 cc of 
non-ionic contrast medium was injected into joint space 
in order to verify the position after the joint capsule was 
passed. Blockade was applied with 1 cc of methylpred-
nisolone (Depo-medrol®; Eczacıbaşı, Turkey) and 1 cc 
of lidocaine HCI (Lidokaine®-ER; Vem İlaç, Turkey).[8]
Age, gender, height, weight and educational status of 
the patients were recorded. Patients were followed up at 
6 month intervals for a mean of 17.7 months.
Pain was evaluated using the Visual Analog Scale 
(VAS). Patients were informed about the use of the pain 
assessment scale (0=no pain, 5=moderate pain, 10=ex-
tremely severe pain) and asked to indicate the pain level 
felt during sleep, rest, activity (walking) on the scale.[9]
The Oswestry Disability Index (ODI) was used to 
determine the pain-related disability level. The question-
naire is composed of 10 subgroups inquiring severity of 
pain, self-care, lifting-carrying, walking, sitting, standing, 
sleep, sexual life, travelling and social life. Total scores 
vary between 0 and 50 and the level of disability increas-
es as the score increases.[10]
The Rivermead Mobility Index (RMI) was used to 
evaluate patient mobility level. The RMI is a uni-dimen-
sional index composed of basic mobility activities and 
focused on measuring mobility status. The self-report 
index is composed of 14 questions and 1 observation 
including activities ranging in difficulty from turning in 
Fig. 1. Distribution of the patients who were included in the study and followed up.
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bed to running. Answers of “yes” are awarded 1 point. 
Scores of 15 points indicate no mobility problem and 
scores of 14 and below indicate mobility problem.[11]
Functional level of the cases was evaluated with 
the 24-item Roland-Morris Disability Questionnaire 
(RMDQ). Total scores were calculated by giving 1 
points to “yes” answers and 0 points to “no” answers.[12]
The SF-36 questionnaire was used to evaluate qual-
ity of life. Developed by the Rand Corporation, it was 
translated into Turkish and validity and reliability study 
performed.[13,14] The form is composed of 36 items mea-
suring 8 dimensions: physical function, social function, 
role limitations due to physical problems, role limita-
tions due to emotional problems, mental health, energy/
vitality, general perception of pain and health. Subscales 
evaluate health between 0 and 100, with 0 indicating 
‘poor health’ and 100 ‘good health’.
Data analysis was performed using SPSS version 
16.0 (SPSS Inc., Chicago, IL, USA). The Kolmogorov-
Smirnov test was used to evaluate normality distribu-
tion, the t- and chi-square tests to analyze the superiority 
of descriptive data in independent groups and the t-test 
to determine the difference between treatment groups.
[15] P values of less than 0.05 were considered significant.
Results
Descriptive data are presented in Table 1. There were no 
significant differences between groups (p>0.05).
Mean duration between surgery and injection was 
27.4±15.5 (range: 12 to 60) months in the fusion group. 
Sacroiliac pain was caused by degenerative spinal dis-
eases in 14 patients and L5-S1 instability in 8 (spondy-
lolysis or spondylolisthesis). Posterior spinal instrumen-
tation and fusion operation was performed at L5-S1 in 
11 patients, L4-S1 in 8 and L3-S1 in 3 (Fig. 1). Grafting 
from the iliac wing was performed in two cases. Allograft 
was used in all patients.
Mean follow-up time was 17.66±6.43 (range: 6 to 29) 
months for patients in the fusion group and 17.83±6.67 
(range: 6 to 30) months in the non-fusion group. Single-
dose injection was performed in 51 (70.8%) patients 
and two doses in 21 (29.2%). Of the 21 patients who 
received two doses, 12 were in the fusion group and 9 
in the non-fusion group. The second dose was injected 
at an average of 5.91±4.65 (range: 1 to 12) months and 
11.16±3.60 (range: 6 to 16) months following the initial 
injection, in the fusion and non-fusion groups, respec-
tively. There was a significant difference in the timing of 
the second dose between groups (p=0.004).
Statistically significant improvements were observed 
when pre-treatment and post-treatment assessments 
were compared in both groups (Tables 2 and 3).
When pre-treatment and post-treatment differences 
of the patients in the fusion and non-fusion groups were 
compared, there was a statistically significant difference 
in favor of the non-fusion group in pain felt during ac-
tivity (p=0.042) and no significant difference in other 
parameters (Table 4).
Discussion
Although SI joint arthrosis develops as a natural pro-
cess of aging, surgical transactions involving the joint 
environment facilitates this process. Previous studies 
have implicated graft harvesting in the development of 
SI pain following spinal fusion surgery.[16,17] However, 
as pain can also develop on the unoperated side, further 
factors have been investigated.[3] The term ‘adjacent seg-
ment degeneration’ aims at explaining additional prob-
lems developing below and above the fusion level, based 
on biomechanics. An ample amount of studies have 
Table 1. Descriptive data of cases. 
  Fusion cases (n=22) Non-fusion cases (n=50)
   Min.-Max. Mean±SD Min.-Max. Mean±SD p*
Age (year) 31-76 50.3±17.3 17-58 38.6±12.3 0.119
Height (cm) 150-185 164.4±10.5 153-182 167.4±9.2 0.532
Weight (kg) 53-93 74±15.1 53-105 78.5±15.5 0.537
BMI (kg/m2) 23.55-32.95 27.1±3.4 19.4-36.2 28.03±5.2 0.672
Educational level (yrs) 5-12 6.8±3.05 5-22 9.6±6.2 0.248
   N (72) %   p†
Gender
 Female  54 75   0.000
 Male  18 25
*: Kolmogorov-Smirnov test. †: Chi-square test. Significant p values are written in bold. SD: Standard deviation.
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shown that fusion operations, terminated at the sacrum 
in particular, facilitate SI joint degeneration whether 
radiologically marked or not and leads to postoperative 
pain.[1-3,7,18] Therefore, in fusion operations terminated 
at the L5 vertebra or sacrum, the SI joint is accepted as 
the distal adjacent segment in which load transmission 
increases.[1,19]
Adjacent segment degeneration should be consid-
ered a different disease from its cause as this clinical con-
dition leads to a new diagnosis and treatment process. 
Table 2. Comparison of overall quality of life, pain, mobility level and disability of non-fusion patients before and after 
treatment.
   Before treatment After treatment t p*
   (n=50) (n=50)  
   Mean±SD Mean±SD 
Pain (VAS)    
 Pain during sleep 7.1±2.5 2.02±2.31 8.565 0.000
 Pain at rest 5.94±1.39 2.16±2.31 9.305 0.000
 Activity pain 9.08±0.98 2.78±3.46 10.386 0.000
Oswestry Disability Index (ODI) 29.35±4.83 14.52±6.95 9.846 0.000
Roland-Morris Questionnaire (RMQ) 9.89±4.77 4.05±2.58 7.295 0.000
Rivermead Mobility Index (RMI) 12.16±2.31 14.35±0.88 -5.575 0.000
Overall quality of life scale (SF-36)
 General health 30.88±16.03 60.29±15.15 -15.385 0.000
 Physical condition 37.05±21.43 75.88±25.07 -4.698 0.000
 Emotional status 55.08±20.34 72.92±22.04 -6.040 0.000
 Social status 34.35±26.80 75.58±16.79 -6.463 0.000
 Physical role limitation 7.35±14.69 76.47±29.93 -8.459 0.000
 Emotional role limitation 9.76±25.68 72.41±35.93 -6.627 0.000
 Pain  18.35±16.35 58.41±14.24 -7.504 0.000
     Energy level 35.58±17.48 54.70±16.81 -5.563 0.000
*Paired samples t-test. Significant p values are written in bold. SD: Standard deviation.
Table 3. Comparison of overall quality of life, pain, mobility level and disability of fusion patients before and after
 treatment.
   Before treatment  After treatment  t p*
   (n=22) (n=22)  
   Mean±SD Mean±SD 
Pain (VAS)    
 Pain during sleep 7.03±2.58 1.61±1.55 9.266 0.000
 Pain at rest 4.92±2.09 0.26±0.66 11.423 0.000
 Activity pain 8.30±1.59 3.11±1.77 11.036 0.000
Oswestry Disability Index (ODI) 28.36±4.85 14.50±6.05 9.647 0.000
Roland-Morris Questionnaire (RMQ) 10.55±6.15 3.33±3.09 8.654 0.000
Rivermead Mobility Index (RMI) 12.11±1.77 14.66±0.48 -6.706 0.000
Overall quality of life scale (SF-36)
 General health 47.33±17.81 71.67±17.08 -6.720 0.000
 Physical condition 48.85±19.91 74.61±19.63 -6.980 0.000
 Emotional status 50.13±17.75 68.53±21.43 9.870 0.004
     Social status 34.35±26.80 75.58±16.79 -6.463 0.000
     Physical role limitation 9.61±19.20 79.61±33.01 -9.592 0.000
     Emotional role limitation 4.44±17.21 55.11±42.94 -10.271 0.000
     Pain  17.67±12.26 60.00±19.36 -8.554 0.000
     Energy level 43.00±13.99 63.33±16.22 -6.625 0.000
*Paired samples t-test. Significant p values are written in bold. SD: Standard deviation.
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The origin of pain in the SI joint following lumbosacral 
fusion may be difficult to define. Adjacent segment de-
generation is always a risk for revision operation.[20]
The role of SI joint blockade has been discussed in 
the treatment of sacroiliitis and positive effects have 
been reported.[7,21] However, it is not yet a proven treat-
ment method and is frequently applied under every con-
dition due to the lack of a consensus about SI joint pain.
[5,6] As instrumented fusion is the only surgical option 
for SI-related problems, SI blockade can be considered a 
non-invasive and effective treatment alternative.
In the present study, the effectiveness of SI blockade 
in the treatment of SI pain following fusion operation 
involving the sacrum was indirectly investigated through 
comparison with non-operated patients. We hypoth-
esized that the effect of SI blockade is lower in patients 
who had undergone fusion and rigid instrumentation as 
the etiology of pain is more complex and multifactorial 
in these patients. Therefore, SI injection does not appear 
to be as effective.
No significant difference was determined between 
two groups and similar improvements in pain and daily 
activities were obtained in fusion and non-fusion pa-
tients. There are few studies that have investigated the 
results of treatment, with the exception of diagnostic in-
jections.[3,4,18] In their study analyzing the effectiveness of 
SI blockade in 39 patients without spondyloarthropathy, 
12 of which had lumbar fusion (4 involving the sacrum), 
Liliang et al. reported a poorer success rate in the fusion 
group.[7] In another study conducted with 14 patients 
(10 involving the sacrum), results of patients with fusion 
were analyzed and short-term outcomes were reported 
to be good.[22] 
In our study, the spinal fusion group was composed 
of patients whose fusion involved the sacrum. Although 
pain is more prominent in patients with fusions termi-
nated at S1, SI joint degeneration also develops in pa-
tients with fusion terminated at L5.[1] Therefore, the 
study group’s being composed solely of fusions termi-
nated at S1 can be considered an advantage of the study. 
While the response of the two cases in which iliac wing 
graft was used was similar to other patients, a statisti-
cal assessment could not be performed due to the small 
number of patients.
A second injection was required in a shorter time in 
the fusion group. Significant differences between groups 
were not observed in parameters, with the exception of 
activity pain (Table 4). Activity pain, a component of the 
pain scale, was greater in the fusion group than the non-
fusion group. However, this pain did not significantly af-
Table 4. Comparison of overall quality of life, pain, mobility level and disability of fusion and non-fusion patients after 
treatment.
   Fusion cases Non-fusion cases  t p*
   (n=22) (n=50)  
   ∆±SD ∆±SD 
Pain (VAS)    
 Pain during sleep 5.94±2.48 7.06±2.15 -1.359 0.184
     Pain at rest 5.41±3.16 5.33±2.55 0.076 0.940
     Activity pain 5.11±2.28 6.66±1.83 -2.092 0.042
Oswestry Disability Index (ODI) 4.72±3.24 5.22±3.97 -0.295 0.774
Roland-Morris Questionnaire (RMQ) 7.00±4.00 8.00±3.93 -0.535 0.600
Rivermead Mobility Index (RMI) 2.66±.86 2.55±.72 0.292 0.772
Overall quality of life scale (SF-36)
     General health 19.93±18.67 24.70±20.65 0.682 0.500
     Physical condition 23.12±13.07 28.52±13.08 0.964 0.345
     Emotional status 13.33±17.05 19.88±20.15 0.985 0.333
     Social status 24.16±24.30 29.411±29.29 0.547 0.589
     Physical role limitation 63.00±38.53 51.32±39.70 -0.842 0.407
     Emotional role limitation 68.88±42.66 56.47±42.03 -0.828 0.414
     Pain  39.37±23.55 41.17±31.69 0.143 0.888
     Energy level 24.00±13.65 22.35±18.96 -0.278 0.783
   Mean±SD Mean±SD t p*
Patient satisfaction level (VAS) 8.07±1.49 8.04±1.67 -0.111 0.913
*Independent samples t-test. Significant p values are written in bold. SD: Standard deviation.
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fect functional status and quality of life.
In conclusion, SI blockade has a similar therapeutic 
effect on patients who underwent lumbosacral fusion 
surgery as on non-operated patients. A different treat-
ment method is not necessary for the treatment of SI 
pain in fusion patients with S1 involvement.
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